Multiple signalling options for prostacyclin

Acta Pharmacologica Sinica

Volumn 24, Issue 7, 2003, Pages 625-630

  Wise, Helen ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Epoprostenol; IP receptors; Peroxisome proliferator activated receptors; Receptor switching

Indexed keywords

CARBACYCLIN; CICAPROST; GUANINE NUCLEOTIDE BINDING PROTEIN; ILOPROST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN RECEPTOR; PROSTACYCLIN RECEPTOR IP; PROSTAGLANDIN E1; UNCLASSIFIED DRUG;

CELL FATE; CELL SPECIFICITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; NONHUMAN; PROTEIN PROCESSING; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; EPOPROSTENOL; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, EPOPROSTENOL; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 0038391490     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structure, properties, and functions. Physiol Rev 1999; 79: 1193-226.
2. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-5.
3. Spisni E, Griffoni C, Santi S, Riccio M, Marulli R, Bartolini G, et al. Colocalization prostacyclin (PGI2) synthasecaveolin-1 in endothelial cells and new roles for PGI2 in angiogenesis. Exp Cell Res 2001; 266: 31-43.
4. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-7.
5. Spencer AG, Woods JW, Arakawa T, Singer II, Smith WL. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 1998; 273: 9886-93.
6. 2. J Biol Chem 1999; 274: 17042-8.
7. 2 receptors. Proc Natl Acad Sci USA 1998; 95: 15792-7.
8. 4 in the nuclear envelope. J Biol Chem 1999; 274: 15719-24.
9. Takechi H, Matsumura K, Watanabe Y, Kato K, Noyori R, Suzuki M. A novel subtype of the prostacyclin receptor expressed in the central nervous system. J Biol Chem 1996; 271: 5901-6.
10. Watanabe Y, Matsumura K, Takechi H, Kato K, Morii H, Björkman M, et al. A novel subtype of prostacyclin receptor in the central nervous system. J Neurochem 1999; 72: 2583-92.
11. Takamatsu H, Tsukada H, Watanabe Y, Cui Y, Kataoka Y, Hosoya T, et al. Specific ligand for a central type prostacyclin receptor attenuates neuronal damage in a rat model of focal cerebral ischemia. Brain Res 2002; 925: 176-82.
12. Wise H, Jones RL. Focus on prostacyclin and its novel mimetics. Trends Pharmacol Sci 1996; 17: 17-21.
13. q-coupled effector signaling. J Biol Chem 2001; 276: 33596-607.
14. Moncada S. Biological importance of prostacyclin. Br J Pharmacol 1982; 76: 3-31.
15. Wise H, Jones RL. Prostacyclin and its receptors. New York: Kluwer Academic/Plenum Publishers; 2000. p1-310.
16. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000; 1483: 285-93.
17. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997; 122: 217-24.
18. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388: 678-82.
19. Takahashi Y, Tokuoka S, Masuda T, Hirano Y, Nagao M, Tanaka H, et al. Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. Br J Pharmacol 2002; 137: 315-322.
20. 2. Science 2002; 296: 539-41.
21. Numaguchi Y, Naruse K, Harada M, Osanai H, Mokuno S, Murase K, et al. Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol 1999; 19: 727-33.
22. Todaka T, Yokoyama C, Yanamoto H, Hashimoto N, Nagata I, Tsukahara T, et al. Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats. Stroke 1999; 30: 419-26.
23. Fitzgerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002; 89 (Suppl): 26D-32D.
24. Barst RJ. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart 1997; 77: 299-301.
25. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodelling. Am J Resp Crit Care Med 2001; 164: 314-8.
26. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999; 103: 1509-15.
27. Katsuyama M, Sugimoto Y, Namba T, Irie A, Negishi M, Narumiya S, et al. Cloning and expression of a cDNA for the human prostacyclin receptor. FEBS Lett 1994; 344: 74-8.
28. Namba T, Oida H, Sugimoto Y, Kakizuka A, Negishi M, Ichikawa A, et al. cDNA cloning of a mouse prostacyclin receptor. J Biol Chem 1994; 269: 9986-92.
29. Miggin SM, Kinsella BT. Investigation of the mechanisms of G protein: effector coupling by the human and mouse prostacyclin receptors. J Biol Chem 2002; 277: 27053-64.
30. Parkinson PA, Parfenova H, Leffler CW. Phospholipase C activation by prostacyclin receptor agonist in cerebral microvascular smooth muscle cells. Proc Soc Exp Biol Med 2000; 223: 53-8.
31. Smith JAM, Amagasu SM, Eglen RM, Hunter JC, Bley KR. Characterization of prostanoid receptor-evoked responses in rat sensory neurones. Br J Pharmacol 1998; 124: 513-23.
32. Kam YW, Chow KBS, Wise H. Factors affecting prostacyclin receptor agonist efficacy in different cell types. Cell Signalling 2001; 13: 841-7.
33. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the β-adrenergic receptor to different G proteins by protein kinase A. Nature 1997; 390: 88-91.
34. i switching. Mol Pharmacol 2002; 62: 1094-102.
35. Lefkowitz RJ, Pierce KL, Luttrell LM. Dancing with different partners: protein kinase A phosphorylation of seven membrane-spanning receptors regulates their G protein-coupling specificity. Mol Pharmacol 2002; 62: 971-4.
36. Hayes JS, Lawler OA, Walsh M-T, Kinsella BT. The prostacyclin receptor is isoprenylated. J Biol Chem 1999; 274: 23707-18.
37. 2 receptors: site-directed mutagenesis reveals the significance of the isoleucine residue at position 323. J Recep Signal Transduction 2002; 23: 83-97.
38. Stitham J, Martin KA, Hwa J. The critical role of transmembrane prolines in human prostacyclin receptor activation. Mol Pharmacol 2002; 61: 1202-10.
39. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91: 197-208.
40. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 1997; 94: 4312-7.
41. Reginato MJ, Krakow SL, Bailey ST, Lazar MA. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor γ. J Biol Chem 1998; 273: 1855-8.
42. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000; 129: 823-34.
43. Lim H, Dey SK. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 2002; 143: 3207-10.
44. Aubert J, Saint-Marc P, Belmonte N, Dani C, Ailhaud G, Ailhaud G. Prostacyclin IP receptor up-regulates the early expression of C/EBPβ and C/EBPδ in preadipose cells. Mol Cell Endocrinol 2000; 160: 149-56.
45. 2: physiological implications. Endocrinology 1992; 131: 2393-8.
46. Aubert J, Ailhaud G, Negrel R. Evidence for a novel regulatory pathway activated by (carba)prostacyclin in preadipose and adipose cells. FEBS Lett 1996; 397: 117-21.
47. Lim H, Dey SK. PPARd functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol Metabol 2000; 11: 137-42.
48. Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S, et al. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 2002; 106: 2397-403.
49. Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T. Prostacyclin-dependent apoptosis mediated by PPARδ. J Biol Chem 2001; 49: 46260-7.
50. 1 in coronary artery smooth muscle cells. Eur J Pharmacol 1998; 345: 213-20.
51. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000; 102: 3130-6.
52. Zhang J, Fu M, Zhu X, Xiao Y, Mou Y, Zheng H, et al. Peroxisome proliferator-activated receptor δ up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J Biol Chem 2002; 277: 11505-12.
53. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 2002; 62: 734-40.